Trial intelligence / Profile preview

Kuvan responsiveness test in phenylketonuria in Norway

2009-012978-12Phase 4Terminated

Sponsor
Merck Serono
Start
Jun 2009
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of sapropterin in phenylketonuria (PKU) and hyperphenylalaninemia (HPA), sponsored by Merck Serono. Started Jun 2009; status: terminated.

02

Drugs

sapropterin
03

Conditions

phenylketonuria (PKU)hyperphenylalaninemia (HPA)

Beyond the preview

Go deeper on 2009-012978-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-012978-12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call